Key result
Discontinuing stimulant supplements linked to ~80% lower risk of significant PVC burden.
Why the study?
Rising use of energy drinks and high-dose pre-workout stimulants may act as an underrecognized trigger for ventricular arrhythmias in young individuals without structural heart disease, and the reversibility of these arrhythmias after stimulant discontinuation required evaluation.
Does discontinuation of stimulant supplements reduce significant premature ventricular complex burden (>5%) and NSVT in young patients with structurally normal hearts?
Observational (n=152)
Does discontinuation of stimulant supplements reduce significant premature ventricular complex burden (>5%) and NSVT in young patients with structurally normal hearts?
Discontinuation of high-dose stimulant supplements in young patients with structurally normal hearts leads to an 80% relative risk reduction in significant PVC burden (>5%) and resolves NSVT in 72.7% of cases at 90 days, identifying stimulant exposure as a modifiable arrhythmic risk factor.
Answers are grounded in this paper and cite their sources.
Stimulant discontinuation was associated with reduced PVC burden in young patients with normal hearts; hypothesis-generating and requires randomized confirmation before practice change.
Introduction The increasing consumption of energy drinks and high-dose pre-workout stimulant supplements has raised concerns regarding their association with ventricular arrhythmias, including non-sustained ventricular tachycardia (NSVT), in young individuals without structural heart disease. Even in the presence of normal cardiac imaging, high-level stimulant exposure may act as an underrecognized arrhythmic trigger. Objective To evaluate ventricular arrhythmias in young patients using stimulant supplements and to assess arrhythmic reversibility after discontinuation. Methods A two-phase longitudinal analytical study was conducted including patients aged 15–40 years presenting with palpitations and NSVT on 24-hour Holter monitoring (April 2024–December 2025). All patients had normal echocardiography, cardiac magnetic resonance imaging, exercise testing, and laboratory evaluation. In Phase 1 (n=152), stimulant use was associated with a significantly higher prevalence of premature ventricular complexes (PVCs) compared with non-users (68% vs 35%). Phase 2 focused on arrhythmic reversibility after stimulant discontinuation (n=81; 90-day follow-up). The primary endpoint was significant PVC burden (>5%), and the secondary endpoint was NSVT occurrence. Results Among the 81 stimulant users included in Phase 2, 59 (72.8%) presented PVC arrhythmias at baseline. Discontinuation of stimulant substances led to a marked reduction in PVC burden >5% on 24-hour Holter monitoring, decreasing from 60.5% at baseline to 12.3% after 90 days (RR 0.20; 95% CI 0.11–0.36; p<0.00001), corresponding to an 80% relative risk reduction and 48% absolute risk reduction (NNT ≈ 2), according to McNemar’s test. Among patients (n=10) with baseline PVC burden <5%, 100% demonstrated improvement: 8 achieved complete resolution and 2 showed reduction to <1%. See Attached 1 NSVT resolved in 72.7% of cases after discontinuation (RR 0.27; 95% CI 0.08–0.87; p=0.016). Persistence of arrhythmia was more frequent in patients with baseline PVC burden >10%, suggesting a dose–response gradient. Conclusion High-dose stimulant supplement use is associated with increased ventricular arrhythmic burden in structurally normal young patients. The statistically robust reversibility observed after discontinuation strengthens the plausibility of a causal relationship and identifies stimulant exposure as a modifiable arrhythmic risk factor in this population traditionally considered low risk. Further large-scale studies are warranted.attached 1
No takes yet. Share an insight, caveat, or question.
Falco et al. (2026) conducted an observational in Ventricular arrhythmias (NSVT and PVCs) associated with stimulant supplement use (n=152). Discontinuation of stimulant supplements vs. Baseline active stimulant supplement use was evaluated on Significant premature ventricular complex (PVC) burden (>5%) on 24-hour Holter monitoring (RR 0.20, 95% CI 0.11-0.36, p=<0.00001). Discontinuation of stimulant supplements reduced PVC burden >5% from 60.5% to 12.3% at 90 days in young patients with normal hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: